In this issue:
Risk of infection with dupilumab for moderate-to-severe atopic dermatitis
Safety of tralokinumab in moderate-to-severe atopic dermatitis
COVID-19 outcomes in atopic dermatitis treated with systemic immunomodulatory agents
Long-term outcomes in pemphigus managed with rituximab vs. azathioprine/mycophenolate mofetil
Mirikizumab in moderate-to-severe plaque psoriasis
Predictors of relapse in psoriasis following withdrawal of ustekinumab
SARS-CoV-2 infections in psoriasis patients receiving systemic/biologic/topical treatment
Patient adherence and persistence of ixekizumab while in a PSP
Please login below to download this issue (PDF)